BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25601959)

  • 1. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
    Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
    Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siltuximab for multicentric Castleman disease.
    Liu YC; Stone K; van Rhee F
    Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
    Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
    Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
    Lyseng-Williamson KA
    BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
    Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siltuximab (Sylvant) for treatment of multicentric castleman's disease.
    Med Lett Drugs Ther; 2015 Jan; 57(1459):e8. PubMed ID: 25555075
    [No Abstract]   [Full Text] [Related]  

  • 7. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
    Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
    Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Kurzrock R
    Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of siltuximab.
    Davis CC; Shah KS; Lechowicz MJ
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
    Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
    Ocio EM; Sanchez-Guijo FM; Diez-Campelo M; Castilla C; Blanco OJ; Caballero D; San Miguel JF
    Am J Hematol; 2005 Apr; 78(4):302-5. PubMed ID: 15795923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siltuximab for Multicentric Castleman Disease-Letter.
    Teipel R; Ordemann R; Proske U; Dietrich F; Mende M; Ehninger G; Kroschinsky F; Platzbecker U
    Clin Cancer Res; 2015 Oct; 21(20):4740. PubMed ID: 26473194
    [No Abstract]   [Full Text] [Related]  

  • 15. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease.
    Neuville S; Agbalika F; Rabian C; Brière J; Molina JM
    Am J Hematol; 2005 Aug; 79(4):337-9. PubMed ID: 16044438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siltuximab: a new option for the management of Castleman's disease.
    Barquero N
    Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
    Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
    Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Is the best treatment for HIV-associated multicentric Castleman disease?
    Bower M; Dalla Pria A
    Clin Adv Hematol Oncol; 2012 Mar; 10(3):207-9. PubMed ID: 22402432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.